Coming Together On CLIA Waivers? Industry Hopes To Recruit Patients, Providers To Push Reform
This article was originally published in The Pink Sheet Daily
Executive Summary
Diagnostic firms formed the Coalition for CLIA Waiver Reform last month with the goal of enlisting patients, labs and physicians in the fight to turn back what they say are unreasonable FDA standards for a test to gain access to the broader market of “waived” labs.
You may also be interested in...
FDA Says Final CLIA Waiver Guidance Eases Burdens; Industry Isn’t Satisfied
Final guidelines to companies developing point-of-care diagnostic tests for use in less sophisticated laboratories offer more leeway in clinical trial design than FDA initially proposed
CLIA-Waived Test Market Increasing As Public Health Concerns Loom
Rapid growth in the adoption of CLIA-waived laboratory tests is causing some unease regarding appropriate use of the tests
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.